LumiraDx Ltd (LumiraDx) is a company that provides point-of-care (PoC) diagnostic tests and solutions. The company is focused on transforming community-based healthcare by giving essential diagnostic information to healthcare practitioners at the time of need, enabling better informed medical decisions to enhance health outcomes while decreasing costs. Its product portfolio includes severe acute respiratory syndrome (SARS) coronavirus 2 (CoV-2) antigen test, SARS-CoV-2 antibody test, INR test, and D-Dimmer test. It offers solutions such as to engage, a patient program; INRstar, an anticoagulation software; and DataWell, a data-sharing solution. The company’s products are built on its proprietary, LumiraDx platform. LumiraDx is also evaluating pipeline products at various stages of development for screening infectious diseases, diabetes, and cardiovascular diseases. The company sells its products through a direct sales force and a network of distributors in the US, Europe, Japan, South Africa, Colombia, and Brazil. LumiraDx is headquartered in London, the UK.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company LumiraDx Ltd
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- LumiraDx Ltd Company Overview
- LumiraDx Ltd Company Snapshot
- LumiraDx Ltd Pipeline Products and Ongoing Clinical Trials Overview
- LumiraDx Ltd - Pipeline Analysis Overview
- Business Description
- LumiraDx Ltd - Key Facts
- LumiraDx Ltd - Major Products and Services
- LumiraDx Ltd Pipeline Products by Development Stage
- LumiraDx Ltd Ongoing Clinical Trials by Trial Status
- LumiraDx Ltd Pipeline Products Overview
- Amira
- Amira Product Overview
- Amira Clinical Trial
- Amira - OTC
- Amira - OTC Product Overview
- LumiraDx - BNP
- LumiraDx - BNP Product Overview
- LumiraDx - Na, K
- LumiraDx - Na, K Product Overview
- LumiraDx - Strep A
- LumiraDx - Strep A Product Overview
- LumiraDX Flu A/B + SARS-CoV-2 Antigen Test
- LumiraDX Flu A/B + SARS-CoV-2 Antigen Test Product Overview
- LumiraDX Flu A/B + SARS-CoV-2 Antigen Test Clinical Trial
- LumiraDx SARS-CoV-2 Ag & RSV Test
- LumiraDx SARS-CoV-2 Ag & RSV Test Product Overview
- LumiraDx SARS-CoV-2 Ag & RSV Test Clinical Trial
- LumiraDx SARS-CoV-2 Ag Ultra Test
- LumiraDx SARS-CoV-2 Ag Ultra Test Product Overview
- LumiraDx SARS-CoV-2 Ag Ultra Test Clinical Trial
- LumiraDx - High Sensitivity Troponin I Test
- LumiraDx - High Sensitivity Troponin I Test Product Overview
- LumiraDx - Tuberculosis Test
- LumiraDx - Tuberculosis Test Product Overview
- LumiraDx - Tuberculosis Test Clinical Trial
- LumiraDx Ltd - Key Competitors
- LumiraDx Ltd - Key Employees
- LumiraDx Ltd - Key Employee Biographies
- LumiraDx Ltd - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- LumiraDx Ltd, Recent Developments
- May 09, 2023: LumiraDx to announce first quarter financial results and host quarterly conference call on May 16
- Apr 06, 2023: LumiraDx announces strategic refocus and cost restructuring program
- Mar 14, 2023: LumiraDx to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Quarterly Conference Call on March 21
- Nov 02, 2022: LumiraDx to Announce Third Quarter Financial Results and Host Quarterly Conference Call on November 9
- Aug 11, 2022: LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 18
- Nov 10, 2021: LumiraDx Reports Third Quarter 2021 Financial Results
- May 19, 2020: Drive through Warfarin Clinic supported by LumiraDx
- Dec 11, 2019: Medica 2019 World Forum of Medicine
- Dec 04, 2019: LumiraDx OPTIMAL study now published
- Aug 29, 2019: LumiraDx launches first-of-its-kind smart diagnostic platform for improved point of care patient testing
- Appendix
- Methodology
- About the Publisher
- Contact the Publisher
- Disclaimer
- LumiraDx Ltd Pipeline Products and Ongoing Clinical Trials Overview
- LumiraDx Ltd Pipeline Products by Equipment Type
- LumiraDx Ltd Pipeline Products by Indication
- LumiraDx Ltd Ongoing Clinical Trials by Trial Status
- LumiraDx Ltd, Key Facts
- LumiraDx Ltd, Major Products and Services
- LumiraDx Ltd Number of Pipeline Products by Development Stage
- LumiraDx Ltd Pipeline Products Summary by Development Stage
- LumiraDx Ltd Ongoing Clinical Trials by Trial Status
- LumiraDx Ltd Ongoing Clinical Trials Summary
- Amira - Product Status
- Amira - Product Description
- Amira - A Study Conducted to Evaluate the Performance of the Amira Covid-19 Test
- Amira - OTC - Product Status
- Amira - OTC - Product Description
- LumiraDx - BNP - Product Status
- LumiraDx - BNP - Product Description
- LumiraDx - Na, K - Product Status
- LumiraDx - Na, K - Product Description
- LumiraDx - Strep A - Product Status
- LumiraDx - Strep A - Product Description
- LumiraDX Flu A/B + SARS-CoV-2 Antigen Test - Product Status
- LumiraDX Flu A/B + SARS-CoV-2 Antigen Test - Product Description
- LumiraDX Flu A/B + SARS-CoV-2 Antigen Test - A Multicenter Study Conducted to Evaluate the Performance of the LumiraDx SARS-CoV-2 & FLU A/B Test, and LumiraDx SARS-CoV-2 & RSV Test at Point of Care Testing Sites
- LumiraDX Flu A/B + SARS-CoV-2 Antigen Test - Clinical Validation of the LumiraDx SARS-CoV-2 & Flu A/B Test in Anterior Nares Nasal Samples For Point-of-Care (POC) Use
- LumiraDx SARS-CoV-2 Ag & RSV Test - Product Status
- LumiraDx SARS-CoV-2 Ag & RSV Test - Product Description
- LumiraDx SARS-CoV-2 Ag & RSV Test - A Multicenter Study Conducted to Evaluate the Performance of the LumiraDx SARS-CoV-2 & FLU A/B Test, and LumiraDx SARS-CoV-2 & RSV Test at Point of Care Testing Sites
- LumiraDx SARS-CoV-2 Ag Ultra Test - Product Status
- LumiraDx SARS-CoV-2 Ag Ultra Test - Product Description
- LumiraDx SARS-CoV-2 Ag Ultra Test - A Multicenter COVID-19 Study Conducted to Evaluate the Performance of the LumiraDx SARS-CoV-2 Ag ULTRA Test at Point of Care Testing Sites
- LumiraDx - High Sensitivity Troponin I Test - Product Status
- LumiraDx - High Sensitivity Troponin I Test - Product Description
- LumiraDx - Tuberculosis Test - Product Status
- LumiraDx - Tuberculosis Test - Product Description
- LumiraDx - Tuberculosis Test - Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined with a CRP Triage Test, Both followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa
- LumiraDx Ltd, Key Employees
- LumiraDx Ltd, Key Employee Biographies
- LumiraDx Ltd, Subsidiaries
- Glossary
- LumiraDx Ltd Pipeline Products by Equipment Type
- LumiraDx Ltd Pipeline Products by Development Stage
- LumiraDx Ltd Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Siemens Healthineers AG
- Almac Diagnostic Services Ltd
- Danaher Corp
- Quest Diagnostics Inc
- Roche Diagnostics Corp
- Abbott Laboratories
- GenMark Diagnostics Inc
- Becton Dickinson and Co
- Diagnostic Potentials Ltd
- Quidel Corp
- Laboratory Corporation of America Holdings - Clinical Trials Testing Division
